secondary acute myeloid leukemia
Information
- Disease name
- secondary acute myeloid leukemia
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03009240 | Active, not recruiting | Phase 1 | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | August 21, 2017 | December 15, 2024 |
| NCT02159495 | Active, not recruiting | Phase 1 | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | December 15, 2015 | December 15, 2024 |
| NCT03333486 | Active, not recruiting | Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | December 7, 2017 | August 28, 2024 |
| NCT00658814 | Active, not recruiting | Phase 2 | Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | December 1, 2008 | March 7, 2025 |
| NCT02890329 | Active, not recruiting | Phase 1 | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | September 5, 2017 | July 1, 2024 |
| NCT02085408 | Active, not recruiting | Phase 3 | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | February 4, 2011 | October 2024 |
| NCT04284787 | Active, not recruiting | Phase 2 | BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia | February 16, 2021 | August 1, 2024 |
| NCT04620681 | Active, not recruiting | Phase 1/Phase 2 | CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML | January 14, 2021 | August 10, 2024 |
| NCT02658487 | Active, not recruiting | Phase 2 | Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia | March 2016 | September 2024 |
| NCT03747757 | Active, not recruiting | Phase 2 | Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue | November 29, 2018 | September 11, 2025 |
| NCT04848974 | Active, not recruiting | Phase 1/Phase 2 | Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia | June 11, 2021 | December 31, 2026 |
| NCT03226418 | Active, not recruiting | Phase 2 | Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia | July 7, 2017 | October 7, 2024 |
| NCT01139970 | Active, not recruiting | Phase 1 | Veliparib and Temozolomide in Treating Patients With Acute Leukemia | May 21, 2010 | February 22, 2025 |
| NCT02530034 | Active, not recruiting | Phase 1 | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | January 31, 2019 | January 31, 2026 |
| NCT01861314 | Active, not recruiting | Phase 1 | Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia | July 3, 2013 | March 7, 2025 |
| NCT04915612 | Active, not recruiting | Phase 1 | Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia | May 21, 2021 | May 1, 2025 |
| NCT00275080 | Completed | Phase 1 | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia | February 2006 | August 2014 |
| NCT00301938 | Completed | Phase 1 | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes | December 2005 | |
| NCT00305773 | Completed | Phase 2 | Vorinostat in Treating Patients With Acute Myeloid Leukemia | January 2006 | January 2010 |
| NCT00309907 | Completed | Phase 2 | Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant | April 2006 | September 2011 |
| NCT00313586 | Completed | Phase 2 | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | August 2006 | July 2013 |
| NCT00322101 | Completed | Phase 3 | Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | January 2006 | October 2014 |
| NCT00331513 | Completed | Phase 1 | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes | March 2006 | |
| NCT00343798 | Completed | Phase 1 | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies | April 2006 | |
| NCT00351975 | Completed | Phase 1 | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | June 2006 | March 2013 |
| NCT00352365 | Completed | Phase 2 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia | June 2006 | July 1, 2011 |
| NCT00357305 | Completed | Phase 1 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | May 2006 | |
| NCT00369317 | Completed | Phase 3 | Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes | March 2007 | December 31, 2021 |
| NCT00016016 | Completed | Phase 1/Phase 2 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia | February 2001 | |
| NCT00408681 | Completed | N/A | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant | June 2006 | May 1, 2015 |
| NCT00445744 | Completed | N/A | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | December 2006 | June 2013 |
| NCT00459212 | Completed | Phase 1 | GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia | March 2007 | |
| NCT00462605 | Completed | Phase 2 | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia | April 2007 | March 2011 |
| NCT00475150 | Completed | Phase 2 | Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | May 2008 | March 2012 |
| NCT00492401 | Completed | Phase 2 | Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | May 2007 | October 2014 |
| NCT00588809 | Completed | Phase 2 | Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia | December 2007 | December 2012 |
| NCT00602771 | Completed | Phase 2 | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia | January 2008 | October 2011 |
| NCT00666588 | Completed | Phase 2 | Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia | April 2008 | December 2012 |
| NCT00703300 | Completed | Phase 1 | Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia | June 2008 | October 2014 |
| NCT00795002 | Completed | Phase 2 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | November 2008 | September 2012 |
| NCT00795769 | Completed | Phase 2 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | August 8, 2008 | June 10, 2009 |
| NCT00799461 | Completed | Phase 3 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | August 2008 | |
| NCT00856388 | Completed | N/A | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | January 14, 2009 | March 13, 2019 |
| NCT00898079 | Completed | Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer | October 13, 2003 | June 30, 2018 | |
| NCT00988715 | Completed | Phase 1 | Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | April 21, 2010 | |
| NCT01005277 | Completed | Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | April 17, 2002 | ||
| NCT01041443 | Completed | Phase 1 | 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | December 2009 | October 2013 |
| NCT01053494 | Completed | N/A | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | April 2010 | February 2012 |
| NCT01093586 | Completed | Phase 2 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | September 2007 | December 2015 |
| NCT01130506 | Completed | Phase 1 | Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 17, 2010 | |
| NCT01132586 | Completed | Phase 1 | Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | May 2010 | January 2014 |
| NCT01174888 | Completed | Phase 1 | Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia | August 2010 | May 2016 |
| NCT01199562 | Completed | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | December 2010 | December 2013 | |
| NCT01231919 | Completed | Phase 1 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | January 2011 | |
| NCT01233921 | Completed | N/A | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer | September 2010 | |
| NCT01238211 | Completed | Phase 2 | Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | December 14, 2010 | March 15, 2021 |
| NCT01273766 | Completed | Phase 2 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | January 2011 | December 2014 |
| NCT01300572 | Completed | Phase 1 | Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS | January 2012 | November 22, 2019 |
| NCT01305200 | Completed | Phase 3 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | March 2011 | June 30, 2015 |
| NCT01307579 | Completed | Phase 3 | Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia | April 4, 2011 | June 30, 2020 |
| NCT01349972 | Completed | Phase 2 | Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | April 2011 | May 2014 |
| NCT01361464 | Completed | Phase 2 | Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia | May 2011 | November 2014 |
| NCT01371656 | Completed | Phase 3 | Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation | September 2011 | June 2017 |
| NCT01427881 | Completed | Phase 2 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | September 2011 | July 2015 |
| NCT01529827 | Completed | Phase 2 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | February 28, 2012 | August 29, 2019 |
| NCT00407966 | Completed | Phase 2 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | October 2006 | November 2009 |
| NCT00025415 | Completed | Phase 1 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | August 2001 | |
| NCT00039117 | Completed | Phase 1 | Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | April 2002 | |
| NCT00045435 | Completed | Phase 2 | Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission | April 2002 | January 2009 |
| NCT00052520 | Completed | Phase 1/Phase 2 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | September 2002 | June 2013 |
| NCT00077181 | Completed | Phase 1 | 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies | January 2004 | |
| NCT00079404 | Completed | Phase 1 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | March 2004 | |
| NCT00085124 | Completed | Phase 3 | Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia | December 2003 | |
| NCT00087204 | Completed | Phase 1 | Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia | May 2004 | |
| NCT00096122 | Completed | Phase 1/Phase 2 | Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia | September 2004 | February 2010 |
| NCT00098423 | Completed | Phase 1 | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | November 2004 | |
| NCT00098826 | Completed | Phase 1 | SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes | December 2004 | |
| NCT00101179 | Completed | Phase 1 | MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | November 3, 2004 | February 3, 2014 |
| NCT00112593 | Completed | N/A | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | November 1999 | |
| NCT00112853 | Completed | Phase 1 | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | March 2005 | |
| NCT00217646 | Completed | Phase 1 | Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia | October 2005 | |
| NCT01567059 | Completed | Phase 2 | Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | May 2012 | June 2013 |
| NCT01588015 | Completed | Phase 1 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | October 29, 2012 | February 2, 2024 |
| NCT01707004 | Completed | Phase 2 | Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 16, 2013 | October 7, 2017 |
| NCT01760655 | Completed | Phase 2 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | December 24, 2012 | December 5, 2022 |
| NCT01798901 | Completed | Phase 1 | AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia | September 17, 2013 | February 19, 2015 |
| NCT01839240 | Completed | Phase 1 | Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia | June 6, 2012 | August 16, 2019 |
| NCT02044796 | Completed | Phase 1/Phase 2 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | January 23, 2014 | April 16, 2018 |
| NCT02093403 | Completed | Phase 1 | Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | March 2014 | November 26, 2016 |
| NCT02126553 | Completed | Phase 2 | Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission | November 13, 2014 | November 30, 2021 |
| NCT02286726 | Completed | Phase 2 | CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia | May 4, 2015 | January 22, 2020 |
| NCT02299518 | Completed | Phase 1 | Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 18, 2015 | March 6, 2018 |
| NCT02316964 | Completed | Phase 1 | Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | April 21, 2015 | December 20, 2019 |
| NCT02323607 | Completed | Phase 1 | Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | January 12, 2016 | July 12, 2018 |
| NCT02397720 | Completed | Phase 2 | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | April 7, 2015 | October 9, 2023 |
| NCT02485535 | Completed | Phase 1 | Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant | September 4, 2015 | July 2020 |
| NCT02583893 | Completed | Phase 2 | Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia | October 7, 2015 | May 17, 2023 |
| NCT02642965 | Completed | Phase 1/Phase 2 | Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | May 2, 2016 | June 30, 2023 |
| NCT02809222 | Completed | N/A | Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls | October 25, 2016 | March 1, 2021 |
| NCT04146038 | Completed | Phase 2 | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | October 26, 2020 | October 25, 2022 |
| NCT04518345 | Completed | Early Phase 1 | TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia | November 5, 2020 | December 22, 2021 |
| NCT05780879 | Not yet recruiting | Phase 2 | A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia | July 2024 | July 2026 |
| NCT05554419 | Not yet recruiting | Phase 2 | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) | August 16, 2024 | January 31, 2025 |
| NCT05807932 | Recruiting | Phase 1/Phase 2 | Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML | June 26, 2023 | January 30, 2028 |
| NCT03041688 | Recruiting | Phase 1 | Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia | February 8, 2018 | June 30, 2025 |
| NCT00357565 | Recruiting | Phase 2 | Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | November 2005 | December 2025 |
| NCT04269213 | Recruiting | Phase 2 | CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old | July 29, 2021 | January 29, 2025 |
| NCT04214249 | Recruiting | Phase 2 | BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia | February 17, 2021 | July 31, 2024 |
| NCT03494569 | Recruiting | Phase 1 | Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome | July 6, 2018 | November 11, 2028 |
| NCT05139004 | Recruiting | Phase 1 | 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | July 19, 2022 | December 13, 2024 |
| NCT03878199 | Recruiting | Phase 1/Phase 2 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | February 20, 2019 | December 31, 2024 |
| NCT05584761 | Recruiting | Phase 1/Phase 2 | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | March 1, 2022 | December 31, 2026 |
| NCT03630991 | Recruiting | Phase 1 | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy | October 11, 2018 | April 30, 2025 |
| NCT05513131 | Recruiting | Phase 2 | Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML | September 30, 2021 | September 30, 2025 |
| NCT05672147 | Recruiting | Phase 1 | CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia | December 7, 2023 | September 3, 2026 |
| NCT02727803 | Recruiting | Phase 2 | Personalized NK Cell Therapy in CBT | May 19, 2016 | May 31, 2025 |
| NCT02115295 | Recruiting | Phase 2 | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | May 19, 2014 | May 31, 2026 |
| NCT00301769 | Terminated | Phase 1 | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia | December 2005 | |
| NCT01203228 | Terminated | Phase 3 | Dose-reduced Versus Standard Conditioning in MDS/sAML | May 2004 | February 2015 |
| NCT00052598 | Terminated | Phase 1/Phase 2 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | September 2002 | June 2011 |
| NCT00049582 | Terminated | Phase 1 | Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | September 2002 | |
| NCT00042796 | Terminated | Phase 1 | Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | December 2002 | |
| NCT02381548 | Terminated | Phase 1 | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia | August 18, 2015 | May 23, 2018 |
| NCT01159067 | Terminated | Phase 2 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | July 2010 | August 9, 2011 |
| NCT02634827 | Terminated | Phase 2 | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation | December 30, 2015 | June 12, 2018 |
| NCT01076270 | Terminated | N/A | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | June 2010 | February 2011 |
| NCT01028716 | Terminated | Phase 2 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | May 19, 2010 | October 7, 2021 |
| NCT00387426 | Terminated | Phase 2 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | September 2006 | February 2009 |
| NCT00096148 | Terminated | Phase 2 | Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | October 2004 | |
| NCT03519984 | Terminated | Phase 1 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia | May 9, 2018 | November 24, 2020 |
| NCT01640301 | Terminated | Phase 1/Phase 2 | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | December 6, 2012 | March 20, 2020 |
| NCT00119366 | Terminated | Phase 2 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 2003 | May 8, 2019 |
| NCT01801046 | Terminated | Phase 1 | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | March 6, 2013 | August 20, 2017 |
| NCT01465386 | Terminated | Phase 2 | Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission | November 2011 | March 2, 2015 |
| NCT01876953 | Terminated | Phase 1/Phase 2 | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia | September 13, 2013 | April 25, 2018 |
| NCT02029417 | Terminated | Phase 2 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | July 2014 | December 2015 |
| NCT01260714 | Terminated | Phase 1 | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia | December 2010 | June 2015 |
| NCT01627041 | Unknown status | Phase 2 | Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia | September 16, 2011 | |
| NCT01619761 | Unknown status | Phase 1 | NK Cells in Cord Blood Transplantation | May 3, 2013 | November 2021 |
| NCT02071901 | Unknown status | Phase 2 | Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy | August 14, 2014 | September 26, 2023 |
| NCT02528877 | Withdrawn | Phase 1 | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | November 2015 | |
| NCT01558778 | Withdrawn | N/A | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant | May 2012 | |
| NCT01652014 | Withdrawn | Phase 2 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | January 2014 | January 2017 |
| NCT03365661 | Withdrawn | Phase 2 | QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML | October 30, 2018 | January 1, 2023 |